Is LXEO or OTLK more profitable?

Oncobiologics' return on equity of 0.00% beat Lexeo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -41.85% -38.03% Oncobiologics N/A N/A -254.82%

Does the media prefer LXEO or OTLK?

In the previous week, Oncobiologics had 6 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 12 mentions for Oncobiologics and 6 mentions for Lexeo Therapeutics. Oncobiologics' average media sentiment score of 1.02 beat Lexeo Therapeutics' score of 0.44 indicating that Oncobiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncobiologics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor XFOR or OTLK?

In the previous week, Oncobiologics had 10 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 12 mentions for Oncobiologics and 2 mentions for X4 Pharmaceuticals. Oncobiologics' average media sentiment score of 1.02 beat X4 Pharmaceuticals' score of 1.02 indicating that Oncobiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncobiologics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OTLK or RCKT more profitable?

Oncobiologics' return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -254.82% Rocket Pharmaceuticals N/A -52.77% -44.92%

Does the media refer more to OTLK or RCKT?

In the previous week, Oncobiologics had 3 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 12 mentions for Oncobiologics and 9 mentions for Rocket Pharmaceuticals. Oncobiologics' average media sentiment score of 1.02 beat Rocket Pharmaceuticals' score of 0.30 indicating that Oncobiologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncobiologics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Oncobiologics (OTLK) Competitors

$0.65 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

OTLK vs. LXEO, XFOR, RCKT, UPB, and LYEL

Should you buy Oncobiologics stock or one of its competitors? Oncobiologics's main competitors and comparable companies include Lexeo Therapeutics (LXEO), X4 Pharmaceuticals (XFOR), Rocket Pharmaceuticals (RCKT), Upstream Bio (UPB), and Lyell Immunopharma (LYEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oncobiologics compare to Lexeo Therapeutics?

Lexeo Therapeutics (NASDAQ:LXEO) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Lexeo Therapeutics has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market.

Lexeo Therapeutics presently has a consensus price target of $18.75, suggesting a potential upside of 284.22%. Oncobiologics has a consensus price target of $4.65, suggesting a potential upside of 618.48%. Given Oncobiologics' higher probable upside, analysts plainly believe Oncobiologics is more favorable than Lexeo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Oncobiologics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Oncobiologics' return on equity of 0.00% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-41.85%	-38.03%
Oncobiologics	N/A	N/A	-254.82%

In the previous week, Oncobiologics had 6 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 12 mentions for Oncobiologics and 6 mentions for Lexeo Therapeutics. Oncobiologics' average media sentiment score of 1.02 beat Lexeo Therapeutics' score of 0.44 indicating that Oncobiologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncobiologics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 2.0% of Lexeo Therapeutics shares are owned by insiders. Comparatively, 1.8% of Oncobiologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Oncobiologics has higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A
Oncobiologics	$1.35M	71.24	-$62.42M	-$0.77	N/A

Summary

Oncobiologics beats Lexeo Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Oncobiologics compare to X4 Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by company insiders. Comparatively, 1.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

X4 Pharmaceuticals has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market.

In the previous week, Oncobiologics had 10 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 12 mentions for Oncobiologics and 2 mentions for X4 Pharmaceuticals. Oncobiologics' average media sentiment score of 1.02 beat X4 Pharmaceuticals' score of 1.02 indicating that Oncobiologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncobiologics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

X4 Pharmaceuticals presently has a consensus price target of $11.25, indicating a potential upside of 178.47%. Oncobiologics has a consensus price target of $4.65, indicating a potential upside of 618.48%. Given Oncobiologics' higher possible upside, analysts clearly believe Oncobiologics is more favorable than X4 Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Oncobiologics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Oncobiologics has lower revenue, but higher earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$15.85M	25.28	-$79.20M	-$1.20	N/A
Oncobiologics	$1.35M	71.24	-$62.42M	-$0.77	N/A

Oncobiologics has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -568.80%. Oncobiologics' return on equity of 0.00% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%
Oncobiologics	N/A	N/A	-254.82%

Summary

Oncobiologics beats X4 Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Oncobiologics compare to Rocket Pharmaceuticals?

Oncobiologics (NASDAQ:OTLK) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

Oncobiologics' return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%

Oncobiologics currently has a consensus price target of $4.65, suggesting a potential upside of 618.48%. Rocket Pharmaceuticals has a consensus price target of $8.57, suggesting a potential upside of 144.20%. Given Oncobiologics' higher possible upside, equities analysts clearly believe Oncobiologics is more favorable than Rocket Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

Oncobiologics has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	71.24	-$62.42M	-$0.77	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Oncobiologics has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

In the previous week, Oncobiologics had 3 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 12 mentions for Oncobiologics and 9 mentions for Rocket Pharmaceuticals. Oncobiologics' average media sentiment score of 1.02 beat Rocket Pharmaceuticals' score of 0.30 indicating that Oncobiologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncobiologics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Oncobiologics beats Rocket Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Oncobiologics compare to Upstream Bio?

Oncobiologics (NASDAQ:OTLK) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Oncobiologics has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. Oncobiologics' return on equity of 0.00% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
Upstream Bio	-4,955.67%	-48.40%	-46.57%

Oncobiologics has higher earnings, but lower revenue than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	71.24	-$62.42M	-$0.77	N/A
Upstream Bio	$2.85M	133.95	-$143.44M	-$2.90	N/A

Oncobiologics has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

In the previous week, Oncobiologics had 12 more articles in the media than Upstream Bio. MarketBeat recorded 12 mentions for Oncobiologics and 0 mentions for Upstream Bio. Oncobiologics' average media sentiment score of 1.02 beat Upstream Bio's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the media.

Company	Overall Sentiment
Oncobiologics	Positive
Upstream Bio	Neutral

11.2% of Oncobiologics shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 16.5% of Upstream Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Oncobiologics presently has a consensus target price of $4.65, indicating a potential upside of 618.48%. Upstream Bio has a consensus target price of $29.67, indicating a potential upside of 325.63%. Given Oncobiologics' higher probable upside, equities analysts plainly believe Oncobiologics is more favorable than Upstream Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Oncobiologics beats Upstream Bio on 9 of the 16 factors compared between the two stocks.

How does Oncobiologics compare to Lyell Immunopharma?

Oncobiologics (NASDAQ:OTLK) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 1.8% of Oncobiologics shares are held by company insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Oncobiologics had 12 more articles in the media than Lyell Immunopharma. MarketBeat recorded 12 mentions for Oncobiologics and 0 mentions for Lyell Immunopharma. Oncobiologics' average media sentiment score of 1.02 beat Lyell Immunopharma's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the media.

Company	Overall Sentiment
Oncobiologics	Positive
Lyell Immunopharma	Neutral

Oncobiologics has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	71.24	-$62.42M	-$0.77	N/A
Lyell Immunopharma	$40K	9,512.13	-$274.45M	-$12.83	N/A

Oncobiologics has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

Oncobiologics currently has a consensus price target of $4.65, indicating a potential upside of 618.48%. Lyell Immunopharma has a consensus price target of $40.86, indicating a potential upside of 163.09%. Given Oncobiologics' higher possible upside, research analysts plainly believe Oncobiologics is more favorable than Lyell Immunopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Oncobiologics has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -920,285.25%. Oncobiologics' return on equity of 0.00% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%

Summary

Oncobiologics beats Lyell Immunopharma on 10 of the 17 factors compared between the two stocks.

Get Oncobiologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OTLK vs. The Competition

Export

Metric	Oncobiologics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$96.17M	$4.00B	$7.32B	$12.82B
Dividend Yield	N/A	3.64%	2.54%	10.78%
P/E Ratio	-0.84	11.68	272.91	24.33
Price / Sales	71.24	1,377.87	639.20	97.25
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	-1.08	17.70	11.38	6.42
Net Income	-$62.42M	-$22.72M	$3.47B	$348.89M
7 Day Performance	-3.72%	2.73%	2.16%	0.51%
1 Month Performance	-53.94%	9.63%	7.59%	4.84%
1 Year Performance	-75.85%	54.98%	25.16%	17.04%

Oncobiologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OTLK Oncobiologics	3.8315 of 5 stars	$0.65 flat	$4.65 +618.5%	-75.9%	$96.17M	$1.35M	N/A	20	Positive News Analyst Revision Gap Up
LXEO Lexeo Therapeutics	2.3339 of 5 stars	$4.94 -2.4%	$18.75 +279.6%	-0.4%	$405.31M	N/A	N/A	58	Gap Up
XFOR X4 Pharmaceuticals	1.8963 of 5 stars	$4.08 +1.2%	$11.25 +175.7%	+3.1%	$404.52M	$15.85M	N/A	80	Positive News
RCKT Rocket Pharmaceuticals	2.6043 of 5 stars	$3.54 +1.7%	$8.57 +142.1%	-3.6%	$388.62M	N/A	N/A	240
UPB Upstream Bio	1.499 of 5 stars	$6.94 +1.3%	$29.67 +327.5%	-60.5%	$380.10M	$2.85M	N/A	38

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OTLK) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncobiologics (OTLK) Competitors

OTLK vs. LXEO, XFOR, RCKT, UPB, and LYEL

How does Oncobiologics compare to Lexeo Therapeutics?

Summary

How does Oncobiologics compare to X4 Pharmaceuticals?

Summary

How does Oncobiologics compare to Rocket Pharmaceuticals?

Summary

How does Oncobiologics compare to Upstream Bio?

Summary

How does Oncobiologics compare to Lyell Immunopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK vs. The Competition

Oncobiologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncobiologics (OTLK) Competitors

OTLK vs. LXEO, XFOR, RCKT, UPB, and LYEL

How does Oncobiologics compare to Lexeo Therapeutics?

Which has more risk & volatility, LXEO or OTLK?

Do analysts recommend LXEO or OTLK?

Is LXEO or OTLK more profitable?

Does the media prefer LXEO or OTLK?

Do insiders and institutionals hold more shares of LXEO or OTLK?

Which has preferable valuation & earnings, LXEO or OTLK?

Summary

How does Oncobiologics compare to X4 Pharmaceuticals?

Do insiders and institutionals have more ownership in XFOR or OTLK?

Which has more volatility and risk, XFOR or OTLK?

Does the media favor XFOR or OTLK?

Do analysts recommend XFOR or OTLK?

Which has higher earnings and valuation, XFOR or OTLK?

Is XFOR or OTLK more profitable?

Summary

How does Oncobiologics compare to Rocket Pharmaceuticals?

Is OTLK or RCKT more profitable?

Do analysts recommend OTLK or RCKT?

Which has preferable valuation & earnings, OTLK or RCKT?

Do insiders & institutionals have more ownership in OTLK or RCKT?

Which has more risk and volatility, OTLK or RCKT?

Does the media refer more to OTLK or RCKT?

Summary

How does Oncobiologics compare to Upstream Bio?

Is OTLK or UPB more profitable?

Which has better valuation and earnings, OTLK or UPB?

Which has more risk and volatility, OTLK or UPB?

Does the media favor OTLK or UPB?

Do institutionals & insiders believe in OTLK or UPB?

Do analysts rate OTLK or UPB?

Summary

How does Oncobiologics compare to Lyell Immunopharma?

Do institutionals & insiders have more ownership in OTLK or LYEL?

Does the media refer more to OTLK or LYEL?

Which has better earnings and valuation, OTLK or LYEL?

Which has more volatility and risk, OTLK or LYEL?

Do analysts rate OTLK or LYEL?

Is OTLK or LYEL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK vs. The Competition

Oncobiologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools